These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21576528)

  • 1. ACP journal club. Quadrivalent HPV vaccine prevented HPV infection and external genital lesions in boys and men 16 to 26 years of age.
    Bender BS
    Ann Intern Med; 2011 May; 154(10):JC5-10. PubMed ID: 21576528
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Quadrivalent HPV vaccine reduced risk for HPV infection and related disease in women 24 to 45 years of age.
    Granwehr BP
    Ann Intern Med; 2009 Oct; 151(8):JC4-12. PubMed ID: 19841449
    [No Abstract]   [Full Text] [Related]  

  • 3. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quadrivalent HPV vaccine is effective prophylaxis against HPV-related external genital lesions in young men.
    Donovan B; Grulich AE
    Evid Based Med; 2011 Oct; 16(5):157-8. PubMed ID: 21561929
    [No Abstract]   [Full Text] [Related]  

  • 5. Updates on human papillomavirus and genital warts and counseling messages from the 2010 Sexually Transmitted Diseases Treatment Guidelines.
    Dunne EF; Friedman A; Datta SD; Markowitz LE; Workowski KA
    Clin Infect Dis; 2011 Dec; 53 Suppl 3():S143-52. PubMed ID: 22080267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP Journal Club. HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women.
    Budenholzer B
    Ann Intern Med; 2012 Jul; 157(2):JC2-6, JC2-7. PubMed ID: 22801705
    [No Abstract]   [Full Text] [Related]  

  • 10. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quadrivalent HPV 6/11/16/18 vaccine].
    Kjaer SK; Andersen ES; Djursing H; Hansen T; Jørgensen JJ; Nilas L; Ottesen BS; Petersen LK; Thomsen SG; Toftager-Larsen K
    Ugeskr Laeger; 2007 Nov; 169(46):3971-4. PubMed ID: 18078651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
    J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The human papillomavirus vaccines.
    Ljubojević S
    Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing an HPV vaccine to prevent cervical cancer and genital warts.
    Bryan JT
    Vaccine; 2007 Apr; 25(16):3001-6. PubMed ID: 17289220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus, genital warts, and vaccines.
    Hsueh PR
    J Microbiol Immunol Infect; 2009 Apr; 42(2):101-6. PubMed ID: 19597640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genital herpes simplex virus infection among men screened for genital papillomavirus].
    Aynaud O; Bijaoui G; Ionesco M; Gorgette O; Poveda JD; Zummer K
    Ann Dermatol Venereol; 1994; 121(5):376-81. PubMed ID: 7702261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.